These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

778 related items for PubMed ID: 15986349

  • 1. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 2. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 3. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 4. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 5. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 6. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D.
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [Abstract] [Full Text] [Related]

  • 7. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 8. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.
    Clin Exp Rheumatol; 2008 Jan; 26(3):401-7. PubMed ID: 18578960
    [Abstract] [Full Text] [Related]

  • 9. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [Abstract] [Full Text] [Related]

  • 10. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
    Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS.
    Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
    [Abstract] [Full Text] [Related]

  • 11. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J, Baraliakos X, Listing J, Sieper J.
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM, Burgos-Vargas R, Laxer RM.
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [Abstract] [Full Text] [Related]

  • 13. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [Abstract] [Full Text] [Related]

  • 14. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 15. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment.
    Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, Chronopoulou E, Trachana M.
    Cytokine; 2008 Jun; 42(3):293-7. PubMed ID: 18445529
    [Abstract] [Full Text] [Related]

  • 16. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [Abstract] [Full Text] [Related]

  • 17. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 18. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N.
    Arthritis Res Ther; 2004 Aug; 6(6):R535-43. PubMed ID: 15535831
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 20. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.